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876Clinical outcome of an extended proximal seal zone
with the AFX endovascular aortic aneurysm system
M. Burress Welborn III, MD,a Huey B. McDaniel, MD,b Ronny C. Johnson, MD,a
Ronald E. Kennedy, MD,b Andrew Knott, MD,a Gerhard H. Mundinger, MD,b Fred S. Stucky, MD,a and
Kenneth Ouriel, MD,c Huntsville, Ala; Jackson, Miss; and New York, NY
Objective: Despite improvements in endograft technology, operator skill, and patient selection, endovascular aneurysm
repair continues to be associated with device-related complications. A retrospective, observational study was undertaken
to evaluate the clinical outcome and imaging ﬁndings of a unique device having externally-mounted, conformable graft
material.
Methods: Infrarenal abdominal aortic aneurysms were treated with the Endologix, Inc AFX endovascular aortic aneurysm
system (Irvine, Calif) endograft in 108 consecutive patients over a 25-month period at two U.S. clinical sites. Baseline
characteristics and procedural outcomes were reviewed by independent monitors. Serial computed tomography (CT)
imaging assessments were performed by an independent core laboratory. Aortic neck characteristics and graft apposition
were analyzed from center line-reformatted CT data sets in 37 patients in an imaging cohort comprising subjects with
high-resolution baseline and follow-up CT imaging for precise assessment of aortic neck characteristics. The mean follow-
up was 11 6 5 months overall, 9 6 6 months in patients with core laboratory imaging, and 5 6 2 months for patients in
the imaging cohort.
Results: Among the 108 patients, 103 (95%) had intact aneurysms and ﬁve (4.6%) were treated for rupture; 80 (74%) were
male and 28 (26%) were female. On average, 2.3 6 0.7 endograft components were implanted per patient and no
adjunctive proximal neck bare stents were used. There were no perioperative deaths in patients with intact aneurysms; two
patients who presented with ruptured aortic aneurysms (40%) died. Major adverse events occurred within 30 days of
implantation in two patients (1.9%) with intact aneurysms. Type II endoleaks were evident on completion angiography in
18 patients (16.7%). Core laboratory analysis of CT studies identiﬁed two patients with type Ia endoleaks (2.3%), two
with type III endoleaks (2.3%), and ﬁve with type II endoleaks (5.7%). Aneurysm-related secondary procedures were
required in ﬁve patients over the ﬁrst year of follow-up (4.6%). No patient developed endograft limb occlusion or
aneurysm rupture and there were no open surgical conversions. In the imaging cohort, 360 graft-to-aortic wall appo-
sition was continuous over a length of 25 6 17 mm and extended the seal zone an average of 5 mm beyond the end of the
anatomic neck. Early sac regression was correlated with neck length (P[ .019) and graft-to-aortic apposition surface area
(P [ .039).
Conclusions: The real-world use of the AFX endograft was associated with a low rate of device-and procedure-related
complications. The ability to achieve an extended seal zone beyond the anatomical neck might in part contribute to
positive outcomes, including the low type Ia and type II endoleak rate. These ﬁndings suggest that the AFX device might
offer some advantages over other currently marketed endografts, but conﬁrmation awaits the availability of longer-term
outcome data. (J Vasc Surg 2014;60:876-84.)Endovascular aortic aneurysm repair (EVAR) is now
the most common technique for repair of infrarenal
abdominal aortic aneurysms (AAAs) in the United States
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://dx.doi.org/10.1016/j.jvs.2014.04.017repair, EVAR is associated with signiﬁcant reductions in
early morbidity and mortality.3,4 Despite these early bene-
ﬁts, however, persistence of beneﬁt beyond the periopera-
tive time frame has not been consistently demonstrated.5-
7 Endograft-related adverse events such as endoleak,
migration, and limb occlusion continue to occur and ac-
count for most late complications and associated secondary
procedures.8 These longer-term device-related events
remain the major limitation of current endovascular ther-
apy and likely underlie the loss of clinical beneﬁt over
open surgical repair beyond the early postoperative
period.9-11
The Endologix Powerlink device (Endologix, Inc,
Irvine, Calif) was available in Europe beginning in 1999
and was commercially approved in the United States in
2004.12 The device was designed as a unibody bifurcated
endograft, which, when positioned directly on the aortic
terminus, has been shown to prevent endograft migration.
The endograft limb conﬁguration paralleled that of the
Fig 1. The AFX (Endologix, Inc, Irvine, Calif) endograft. Illus-
tration provided by Endologix, Inc; reproduced with permission.
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endograft limb occlusion in multiple clinical trials. The
Endologix AFX endovascular AAA system (AFX) repre-
sents the second generation of the Endologix endograft
system and uses novel STRATA high-density expanded
polytetraﬂuoroethylene (ePTFE) graft material.13 The
AFX device has been commercially available since 2011.
Unique to this device, the graft material is externally
mounted and attached only at the proximal and distal
ends of the stent. This design, known as ActiveSeal, allows
the conformable STRATA material to move independent
of the stent and accommodate varied shapes of the prox-
imal neck and aortic bifurcation. This study is the ﬁrst clin-
ical report of the AFX endograft system, assessed in a
real-world patient population emblematic of contemporary
clinical practice.
METHODS
This retrospective, multicenter, single-arm observa-
tional study was conducted at two U.S. clinical sites:
Huntsville Hospital (Huntsville, Ala) and St. Dominic Hos-
pital (Jackson, Miss). The study was approved by the institu-
tional review boards at the two sites and each exempted the
study from patient informed consent based on its retrospec-
tive design and limitation to data collection. Consecutively
treated patients who underwent infrarenal AAA repair with
the Endologix AFX endograft were included in the study,
representing the vast majority of the total infrarenal endovas-
cular volume at the two sites. Computed tomography (CT)
studies were submitted for core laboratory analysis and un-
derwent a quality assurance process whereby CT images
were rejected when the quality was insufﬁcient for three-
dimensional reformatting and accurate determinations of
vascular diameters and angulation. In addition to the CT
images from patients comprising the overall data set, a sub-
set of patients with high-resolution baseline and follow-up
CT scans comprised the imaging cohort and underwent a
comprehensive analysis of the proximal aortic neck anatomy
and its relationship to clinical and anatomic outcomes.
AFX device. The AFX device is a bifurcated unibody
endograft with STRATA ePTFE material external to the
stent (Fig 1). The device rests on the aortic bifurcation
to provide anatomic ﬁxation and the proximal extension,
available with or without a bare suprarenal stent, provides
sealing at the aortic neck. During the course of study, the
AFX bifurcated device was available in diameters of 22, 25,
and 28 mm and lengths ranging from 40 to 120 mm
(body) and 30 to 55 mm (limbs). The proximal extension
that was placed adjunctively to achieve a proximal seal was
available with or without a suprarenal bare stent (20-mm
length) and was supplied in diameters ranging from 22 to
34 mm and covered lengths from 55 to 100 mm. When
needed, iliac limb extension diameters ranged between 16
and 25 mm in straight, tapered, ﬂared, and stepped con-
ﬁgurations. The device is delivered with the 17-French
AFX Introducer System ipsilaterally and 9-French sheath
contralaterally. With these components, the AFX device is
indicated for patients with an aortic neck length of$15 mm, neck diameter $18 mm and #32 mm, and
infrarenal angulation to the aneurysm of #60. The indi-
cated iliac seal zone length is $15 mm, accommodating
common iliac artery diameters of $10 mm and #23 mm.
Unique to this device, patients with acceptable unilateral
access vessel diameter can be treated.
Study deﬁnitions and end points. Baseline comorbid-
ities were classiﬁed according to the Society for Vascular
Surgery reporting standards for endovascular aneurysm
repair.14 Clinical data abstracted from the patient charts
included demographic characteristics, baseline medical
comorbidities, procedural characteristics, and adverse
events. Adverse events were deﬁned using the criteria of
the Society of Vascular Surgery reporting standards after
medical device use.15,16 Major adverse events (MAEs)
were deﬁned consistent with the Lifeline registry to include
the composite of all-cause death, bowel ischemia, myocar-
dial infarction, paraplegia, renal dysfunction (reduction in
glomerular ﬁltration rate of >30% from the preoperative
value), renal failure (need for dialysis or increase in serum
creatinine of >0.5 mg/dL on two successive tests,
compared with the preoperative level), respiratory failure
(need for mechanical ventilatory support beyond 24 hours
after the procedure), or stroke.15
The baseline imaging study for assessment of aneurysm
sac diameter change was deﬁned as the ﬁrst postoperative
CT scan if performed within 3 months of endograft
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was used. Aortic neck thrombus and calcium were graded
on a scale of 0, 1, or 2 deﬁned as: 0 ¼ <1 mm in thickness;
1 ¼ $1 mm in thickness and <180 in circumference; and
2 ¼ $1 mm in thickness and $180, respectively. Aneu-
rysm sac enlargement was deﬁned as an increase of
>5 mm in the maximum aneurysm diameter compared
with the baseline imaging study. Endograft migration was
deﬁned as graft movement >10 mm compared with the
original implant location. Secondary procedures were
deﬁned as reinterventions performed for complications
related to the aneurysm or its repair, exclusive of diagnostic
procedures.16 They were then categorized by relatedness to
the device. Type I and type III endoleaks were considered to
be device-related interventions and type II endoleaks were
considered to be interventions unrelated to the device.
Patients in the imaging cohort represented all patients
with baseline and follow-up CT imaging studies of
adequate resolution to precisely assess the characteristics
of the proximal aortic neck including endograft-to-aortic
apposition. Maximum aneurysm diameter, aortic neck
diameter, infrarenal, and suprarenal neck angulation mea-
surements were performed on three-dimensional reformat-
ted CT data sets. Anatomic aortic neck length was
measured as the neck length where the aortic diameter
remained within 10% of its diameter at the lowest renal
artery. The aortic apposition surface area was calculated
as the area over which the endograft material was in contig-
uous contact with the aortic wall measured over the aortic
length that exhibited 360 material apposition.
Data collection and statistical analyses. Baseline clin-
ical, procedural, and follow-up data were collected by in-
dependent site monitors. Lists of consecutive patients
treated with the AFX device were prepared by the sites and
each inpatient and outpatient record was reviewed by the
monitors using standardized data collection forms. Baseline
and follow-up CT imaging studies were assessed at a core
laboratory (Syntactx, New York, NY). The mean follow-up
was 11 6 5 months overall, 9 6 6 months in patients with
core laboratory imaging, and 5 6 2 months for patients in
the imaging cohort. Results are expressed as mean 6
standard deviation for continuous variables and frequencies
for categorical variables. The degree of univariate associa-
tion between proximal neck anatomic variables and sac
regression was evaluated using the Pearson correlation
coefﬁcient. P < .05 was considered statistically signiﬁcant,
using the Holm-Bonferroni method to control for multiple
family-wise error.17
RESULTS
Study population. Over the period between June
2011 and February 2013, 108 consecutive patients were
treated with the Endologix AFX device at Huntsville Hos-
pital (41 patients) and St. Dominic Hospital (67 patients).
There were 103 patients treated electively for intact aneu-
rysms (95.4%) and ﬁve treated urgently for rupture (4.6%).
The baseline characteristics of the treatment groups are dis-
played in Table I. Most patients were male (74%) andCaucasian (84%) with a mean body mass index of 27.9 6
5.5. The most common comorbidities included hyperten-
sion (89%), tobacco use (82%), and hyperlipidemia (66%);
88% of the patients were American Society of Anesthesi-
ologists physical status class 3 (55%) or 4 (33%; Table II).
In core laboratory analysis, aneurysms averaged 50 6
12 mm in maximum diameter at baseline (Table III).
The proximal aortic neck length averaged 24 6 17 mm;
40% of the necks were <15 mm and 26% were <10 mm
in length. Proximal aortic neck diameter averaged 26 6
7 mm and 26% had a conical conﬁguration. Thrombus
and calcium were present within the aortic neck in 36%
and 40% of the patients, and were categorized as grade 2
in 7.9% and 2.4%, respectively. The mean infrarenal aortic
neck angulation was 20 6 12 (range, 1-57). A narrow
distal aortic bifurcation (#20 mm in diameter) was present
in 20% of the group. Aortic neck anatomy fell outside of
the AFX instructions for use (IFU) in 52% of the cases,
with aortic neck length <15 mm in 42%, neck diameter
>32 mm in 6%, and both in 4% of the patients.
Endograft implantation. Access was accomplished
through bilateral open femoral exposures in 25 patients
(23%) and through an ipsilateral open exposure and contra-
lateral percutaneous access in the remaining 83 patients
(77%; Table IV). The repair was performed with two
AFX components (bifurcated and proximal extension
endografts) in 80 patients (74%) with a mean of 2.3 6 0.7
components (range, 1-5 components) implanted per pa-
tient. The median ﬂuoroscopy time was 25 minutes (range,
11-160 minutes) and a median of 100 mL (range, 25-
200 mL) of contrast was administered. The procedure time
from incision to closure averaged 151 6 65 minutes. The
estimated blood loss averaged 238 6 171 mL and was
>1000 mL in two patients, both with intact aneurysms.
Transfusions were required in nine patients (8.3%); four in
patients with ruptured aneurysms (80%), and ﬁve in
patients with intact aneurysms (4.9%). Access site compli-
cations occurred in four patients (3.7%) and included two
femoral artery injuries (1.9%), one iliac arteriovenous ﬁstula
(0.9%), and one iliac perforation (0.9%); the latter two of
which resolved with placement of covered stents. There
were two patients with misplacement of the proximal
extension (1.9%); both were addressed with the placement
of an additional proximal extension endograft to bridge the
gap.
Clinical outcome. In-hospital MAEs occurred within
30 days of endovascular aneurysm repair in ﬁve patients
(4.6%); two patients (1.9%) with intact aneurysms and
three patients (60%) with ruptures (Table V). Between
30 days and 12 months, MAEs occurred in an additional
seven patients, all in the intact aneurysm group, accounting
for an MAE rate of 13.6% in patients with intact aneurysms
through 12 months. There were no perioperative deaths in
the patients with intact aneurysms and two (40%) of the
patients with ruptured aneurysms died within 30 days.
There were ﬁve additional deaths over the ﬁrst 12 months
of follow-up, all in patients with intact aneurysms. The
12-month all-cause mortality rate was 6.5% overall and
Table II. Baseline comorbidities
Comorbidity Value (N ¼ 108), No. (%)
Hypertension 96 (88.9)
Tobacco use 89 (82.4)
Hyperlipidemia 71 (65.7)
Coronary artery disease 52 (48.1)
Previous abdominal operation 44 (40.7)
Obesity 31 (28.7)
Chronic obstructive lung disease 29 (26.9)
Diabetes mellitus 22 (20.4)
Malignancy 20 (18.5)
Renal failure/dysfunction 20 (18.5)
Previous myocardial infarction 20 (18.5)
Cardiac arrhythmia 18 (16.7)
Stroke/transient ischemic attack 17 (15.7)
Heart failure 12 (11.1)
Table I. Baseline demographic characteristics of the
study population
Demographic parameter Value (N ¼ 108), No. (%)
Sex
Male 80 (74)
Female 28 (26)
Racea
Caucasian 64 (84)
Black 12 (16)
Weight, kg
Mean (SD) 86.0 (18.9)
Median 85.7
Minimum, Maximum 49.1, 164.1
Height, cm
Mean (SD) 175.6 (9.2)
Median 177.8
Minimum, Maximum 154.2, 195.6
Body mass index
Mean (SD) 27.9 (5.5)
Median 27.4
Minimum, Maximum 16.4, 50.3
SD, Standard deviation.
aRace was not reported in 32 patients.
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related deaths in this latter group.
There were no aneurysm ruptures after repair, no open
surgical conversions, and no stent fractures or ePTFE ma-
terial disruptions were observed. Aneurysm-related second-
ary procedures were performed in six patients (5.6%), two
(1.9%) within 30 days and two (1.9 %) between 30 days
and 1 year, and two (1.9%) thereafter (Table VI). Early
procedures were performed for inadequate overlap be-
tween the extension and the main body, one without and
one with CT ﬁndings of a type III endoleak. The patients
were treated with aortic cuffs on the second and 10th post-
operative days, respectively. A type Ib endoleak was treated
on postoperative day 107 with placement of an iliac exten-
sion. A type Ia endoleak was treated on postoperative day
460 with deployment of an aortic extension cuff and a giant
Palmaz stent (Cordis Endovascular, Warren, NJ). A typeIII endoleak was detected on postoperative day 96 in a pa-
tient with bilateral common iliac aneurysms, embolization
of one hypogastric artery, and deployment of two limbs
from the contralateral AFX limb to the hypogastric and
external iliac arteries. The endoleak was initially observed
without intervention, but was eventually treated on post-
operative day 473 with an additional iliac bridging endog-
raft from the AFX limb to the external iliac artery, thereby
excluding the endoleak at the junction of the three original
endografts.
There were no iliac limb occlusions during follow-up.
An iliac limb stenosis was detected in one patient at
5 months. The stenosis was at the midportion of the
limb and thought to be the result of a kink. It was success-
fully treated with balloon angioplasty and stent placement
on the 157th postoperative day.
Endoleaks. The frequency of endoleaks observed at
completion angiography and follow-up CT imaging is
listed in Table VII. Endoleaks at the completion of angi-
ography were reported by the sites in 18 patients (16.7%)
and all classiﬁed as type II.
Follow-up contrast CT imaging studies of adequate
quality were available in 87 patients and each was reviewed
by the core laboratory (Table VII). Over a mean follow-up
of 9 6 6 (range, 1-24) months, core laboratory analysis
documented type Ia endoleaks in two patients (2.3%) and
type II endoleaks in ﬁve patients (5.7%). A type III endo-
leak was evident on CT imaging performed on the ﬁfth
postoperative day, because of deployment of the proximal
extension with inadequate overlap of the main body (noted
previously). The patient underwent placement of an addi-
tional proximal extension between the two components
10 days after the index procedure, with resolution of the
endoleak. Another type III endoleak was discovered on
postoperative day 96 at the junction of the AFX limb
with the hypogastric and external iliac endografts
(described previously).
Among the 18 patients with type II endoleaks at
completion of arteriography, 12 had adequate CT imaging
after the procedure and all but two of these endoleaks
resolved spontaneously by the ﬁrst imaging study. Type
II endoleaks were observed in three additional patients
over follow-up. None of the ﬁve type II endoleaks were
treated and no aneurysm enlarged.
A single type Ib endoleak was reported by the site but
imaging studies were unavailable for core laboratory anal-
ysis. This patient was successfully treated with an iliac
extension 107 days after the initial endovascular repair
(noted previously). Among the two type Ia endoleaks,
one was found 456 days after endograft implantation and
occurred in a patient with a short aortic neck (9 mm in
length with grade 1 mural calcium). In retrospect, this
endoleak was evident on the core laboratory analysis of a
CT study performed 33 days after endograft implantation.
The second type Ia endoleak occurred in a female patient
treated for a 63-mm AAA with an aortic neck 8 mm in
length with abundant thrombus and severe angulation.
This patient had multiple medical comorbidities, was
Table III. Anatomic measurements (core laboratory reported)
All patients (N ¼ 87) Intact (n ¼ 83) Ruptured (n ¼ 4)
Aneurysm diameter, mm 50 6 12 48 6 9 82 6 14
Aortic neck length, mm 24 6 17 23 6 18 9 6 9
Neck length <10 mm 21/81 (26) 18/77 (23) 3/4 (75)
Neck length <15 mma 32/81 (40) 29/77 (38) 3/4 (75)
Infrarenal neck angulation (degrees) 20 6 12 18 6 13 18 6 10
Proximal neck diameter, mmb 25 6 6
Conical neck conﬁguration 21/81 (26) 18/77 (23) 3/4 (75)
Neck calcium (grade 1 or 2) 34/86 (40) 32/82 (39) 2/4 (50)
Neck thrombus (grade 1 or 2) 26/73 (36) 25/72 (35) 1/1 (100)
Data are expressed as mean 6 standard deviation for continuous variables and frequency (%) for categorical variables.
aIncludes aortic necks <10 mm in length.
bThe number of patients with assessable neck diameter was inadequate in the group with ruptured aneurysms. The values in the text differ slightly because they
include all aneurysms, intact and ruptured.
Table IV. Patient in-hospital data
Variable Value (N ¼ 108)
Access, No. (%)
Bilateral open 25 (23)
Ipsilateral open, contralateral percutaneous 83 (77)
Bilateral percutaneous 0
Mean procedure time 6 SD, minutes
Incision to closure time 151 6 65
Device implant timea 96 6 60
Estimated blood loss, mL 238 6 171
Transfusion required, No. (%) 9 (8.3)
Median contrast volume (range), mL 100 (25-200)
Median ﬂuoroscopy time (range), minutes 25 (11-160)
Mean devices implanted 6 SD 2.3 6 0.7
Components, No. (%)
1 4 (3.7)
2 80 (74)
3 16 (15)
4 6 (5.6)
5 2 (1.9)
Median intensive care unit stay (IQR), days 1 (1, 1)
Median length of hospitalization (IQR), daysb 2 (1, 3)
IQR, Interquartile range; SD, standard deviation.
aFrom insertion of the delivery system to completion of angiography.
bThe mean length of hospitalization in patients with ruptured aneurysms
was 10.4 days.
Table V. Safety outcomes in patients with intact
aneurysms (ﬁrst occurrence)
Outcome
Days
0-30 30-360
MAE
All-cause death 0 6 (5.8)
Bowel ischemia 0 0
Myocardial infarction 0 0
Paraplegia/paraparesis 0 0
Renal dysfunction/failure 0 0
Respiratory failure 2 (1.9) 1 (1.0)
Stroke 0 0
Patients with $1 MAE 2 (1.9) 7 (6.8)
Aneurysm-related mortality 0 0
Aneurysm rupture 0 0
Open surgical conversion 0 0
Endograft limb occlusion 0 0
Endograft migration 0 1 (1.0)
Stent fracture 0 0
MAE, Major adverse event.
Data are expressed as frequency (%).
JOURNAL OF VASCULAR SURGERY
880 Welborn et al October 2014American Society of Anesthesiologists class 4, and was not
considered to be a candidate for open surgical repair. The
endoleak was ﬁrst seen at 9 months in conjunction with
proximal endograft migration and sac enlargement. A psoas
abscess was drained percutaneously and grew Enterococcus.
The patient progressively deteriorated from sepsis and res-
piratory failure. The patient’s family withdrew support and
the patient expired without reintervention 295 days after
the index procedure.
Imaging cohort. In the imaging cohort, the STRATA
material was circumferentially opposed to the aortic wall
over a length of 25 6 17 mm. On average, full apposition
continued 5.1 6 13 mm distal to the end of the anatomic
neck and exceeded the anatomic neck length in 20 of 37 pa-
tients (54%). The mean graft-to-aortic apposition surface area
was 19 6 13 cm2. Early sac regression averaged 0.4 6
0.7 mm/mo. Sac regression was signiﬁcantly correlated withgreater apposition surface area (P ¼ .039) and longer neck
length (P ¼ .019). There were no statistically signiﬁcant re-
lationships between sac regression and smaller neck diameters,
greater neck angulation, or larger baseline aneurysm diameter.
DISCUSSION
The goal of open surgical or endovascular repair of an
AAA is to achieve long-term isolation of the weakened
aneurysmal aortic wall from pressurized arterial blood
ﬂow, thereby protecting a patient from aneurysm rupture
and death. As a prophylactic procedure in patients with
intact aneurysms, this objective must necessarily be
achieved with minimal morbidity and mortality such that
the procedural risks do not outweigh the risks of the dis-
ease. Endovascular techniques are premised on this caveat,
with the primary objective of effective long-term prevention
of aneurysm rupture without the early morbidity of tradi-
tional open surgical repair.18 For the most part, EVAR has
accomplished this aim. Device technology and operator skills
Table VI. Aneurysm-related secondary procedures
Event Group Procedure Days after implantation
Proximal extension misdeployeda Intact Placement of proximal extension 2
Proximal extension misdeployed Intact Placement of proximal extension 10
Type Ib endoleakb Intact Placement of iliac extension 107
Iliac limb kink Intact Deployment of a covered stent 157
Type Ia endoleak Intact Proximal extension cuff and bare stent 460
Type III endoleak Intact Exclusion with an iliac extension 473
CT, Computed tomography.
aThere was no CT evidence of an endoleak in this patient.
bCT was not available for review; this event was site-reported only and was not included in the core laboratory data set.
Table VII. Endoleak and aneurysm sac diameter changes
Completion angiography (site-reported)
CT scan (core laboratory-reported)
0 to 30 days 30 days to 12 months Alla
Patients with imaging, No. 108 12 60 87
Endoleak type, No. (%)
Ia 0 0 2 (3.3) 2 (2.3)
Ib 0 0 0b 0
II 18 (16.7) 1 (8.3) 4 (6.7) 5 (5.7)
III 0 1 (8.3) 1 (1.7)c 2 (2.3)
IV 0 0 0
Undetermined 0 0 0 0
Sac diameter change, No. (%)d
Regression (>5 mm) 10/74 (14)
No change 63/74 (85)
Enlargement (>5 mm) 1/74 (1.4)
CT, Computed tomography.
aIncludes 15 images obtained more than 12 months after implantation.
bA type Ib endoleak was site-reported 107 days after implantation. The CT scan was not available for core laboratory analysis and it is not included in this table.
cThis type III endoleak occurred at the junction of the AFX (Endologix, Inc, Irvine, Calif) limb with additional covered stents to the hypogastric and external
iliac arteries.
dData on 74 patients with baseline and follow-up imaging of adequate quality.
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rates are well below those associated with open surgical
repair.3 Still, anatomic variations render EVAR unsuitable
in a signiﬁcant proportion of patients with AAA.19-22 As
well, effective and long-lasting aneurysm sac depressuriza-
tion after EVAR is not universal. Failures can be categorized
into three general categories of complications: (1) those
from ineffective sealing or ﬁxation at the endograft-to-
vessel attachment sites, (2) those from branch vessel
backﬂow into the sac, and (3) those from durability or
thrombotic issues related to the device, its components, or
their conformation within the aortoiliac anatomy.
The Endologix AFX endograft was designed to
address some of the limitations of current EVAR technol-
ogy. The deployment of endografts suitable for aortic
necks up to 32 mm in diameter can be performed with
17-French ipsilateral and 9-French contralateral intro-
ducer sheaths; a feature important in patients with small
or diseased iliac arteries. The contiguous design of the
main body and iliac limbs eliminates the potential for
modular disconnection at this location. A possibility of
disunion of the proximal aortic and main body compo-
nents, however, does exist. The two cases in the currentseries highlight the need to assure adequate overlap dur-
ing deployment. Placement of the endograft bifurcation
directly on the aortic terminus has been shown to prevent
the risk of endograft migration, as does the bare proximal
stent integral to the suprarenal proximal extension
component. The AFX design facilitates repair with a min-
imal number of components, potentially saving time and
cost of the procedure. A mean of 2.3 devices were used
in the current study, somewhat less than the number of
components per procedure in the recent U.S. investiga-
tional device exemption (IDE) trials.23-25
The use of STRATA conformable ePTFE material
located external to the stent (ActiveSeal) is a design element
directed at improved sealing with the anatomy, which is
particularly advantageous in an irregularly shaped, short,
angulated, or otherwise challenging proximal aortic neck
or distal seal zone. The column strength and location of
the bifurcated graft on the aortic bifurcation optimizes the
role of the proximal stent for sealing with STRATA without
reliance solely on the radial strength of the stent. Optimizing
the radial force of the proximal stent also holds potential to
diminish the risk of long-term late aortic neck dilatation.
STRATA high-density ePTFE material is responsible for
Fig 2. Example of lumbar vessels before endograft implantation (arrows; left panel) and after endograft implantation (right
panel). The pair of lumbar vessels is no longer patent after the graft has been deployed. Illustration provided by Syntactx.
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common occurrence with newer, lower-proﬁle devices.26,27
Type IV leaks, although of little clinical consequence over
long-term follow-up, can be bothersome at the time of im-
plantation because angiographic differentiation with type I
and III endoleaks can be difﬁcult to make.
The results of this ﬁrst report of the AFX conﬁrms
excellent clinical outcome in a real-world, carefully stud-
ied patient population, despite challenging aortic anat-
omy; 40% the study group had an aortic neck <15 mm
in length and 26% were <10 mm in length. The rate of
MAEs, secondary procedures, endoleaks, and endograft
migration was similar to that observed in IDE trials.27-30
There were no limb occlusions, ruptures, or open surgical
conversions. A consideration of the endoleaks observed in
the current series attains importance, from the standpoint
of type Ia endoleaks that continue to occur in certain
high-risk anatomic presentations and the extraordinarily
low rate of type II endoleaks overall. Among the two
type Ia endoleaks observed in the current series, both
were performed on high-risk patients who fell well outside
of the AFX IFU with aortic neck lengths <10 mm. Such
patients would be excluded from IDE trials, but are often
treated in a real world setting in the absence of other ther-
apeutic options.31 The low incidence of type II endoleaks
is interesting and also warrants comment. Type II endo-
leaks were observed in only 6.7% of patients through
12 months; a rate that is contrasted with a frequency as
high as 34% in the recent TriVascular Ovation (TriVascu-
lar, Inc, Santa Rosa, Calif) IDE trial.25 Other than the
Endologix Nellix device, traditional endografts do not
address the aneurysm sac and therefore, intuitively, type
II leaks should be device-independent. The absence of
endograft limb occlusions is noteworthy considering the
relatively high proportion of female patients in this series.
The low rate of type II endoleaks in the current study
must be considered in the context of the sample size andthe length of follow-up. There are at least three potential
explanations for the observed rate of type II endoleaks.
First, the upper 95% conﬁdence interval for type II endo-
leaks through 12 months was 16%; a rate closer to the
experience with most other endografts. Second, the Active-
Seal design might enable the coverage of lumbar vessels
just below the aortic neck and distally within the aortic
sac as the device rests on the aortic bifurcation, particularly
in conjunction with the relatively large diameter of the AFX
main body (Fig 2). A third explanation might relate to the
aneurysm sac hemodynamics imparted by systolic-diastolic
movement of the STRATA material. In a nonthrombosed
sac, expansion of the graft material during systole might
create a transient increase in sac pressure, counteracting
backﬁll from patent inferior mesenteric and lumbar arteries.
Arguing against the latter two mechanisms, however, is the
observation that approximately 17% of patients exhibited
type II endoleaks on completion of angiography; at a
time when branch vessel coverage and any sac pressure
effects would be operative. Additional studies are required
to prove or disprove these hypotheses.
CONCLUSIONS
The results of this ﬁrst U.S. clinical series of the AFX de-
vice conﬁrm its safety and efﬁcacy in a real-world population of
patients, many with challenging aortic neck, aortic bifurcation,
and iliac artery anatomy. Noting that only 48% of patients fell
within the device aortic neck IFU criteria, the observations are
not entirely comparable with premarket approval studies with
more restricted eligibility criteria. Nevertheless, the rate of
most outcome end points including endoleak, endograft
migration, limb occlusion, and sac enlargement are similar
or improved over the data from previous studies. In this re-
gard, the AFX device appears to have great utility over the
broad spectrum of AAA patients and aortoiliac anatomy
encountered in the clinical setting. Deﬁnitive conclusions,
however, await the availability of longer-term follow-up data.
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their early experience with the Endologix AFX (Irvine, Calif) with
the so-called “Activeseal” endovascular device in more than 100patients with infrarenal aortic aneurysmdapproximately 40%
outside the instructions for usedwith excellent midterm results;
no ruptures, no limb occlusions, no stent fractures, and no
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884 Welborn et al October 2014aneurysm-related deaths. In the words of Spence Taylor, “What’s
not to like?”
As an aside, I would remind the audience that Teﬂon is slick. I
used a 20-mm limb extension to cover an aortic pseudoaneurysm in
a young patient after a thoracic gun shot wound a few years ago. I
was dismayed to ﬁnd on a follow-up computed tomography scan
that the covered stent had migrated distally, covering the celiac
trunk. It was just such migration with the ancestral version of this
graft that led to the current strategy to build up from the aortic
bifurcation.
1. Neck dilation. The AFX device joins a family of new endovas-
cular devices that includes most notably the Endologix Nellix
and Trivascular Ovation that share unique design features
that achieve aneurysm exclusion without applying constant
outward force on the aortic neck. Virtually all of the traditional
endovascular aortic aneurysm repair devices have reported vary-
ing degrees of “neck dilation” after long-term follow-up, and
yet, the development of proximal endoleaks is distinctly un-
common if the device is implanted into a normal aortic neck.
My ﬁrst question is, does neck dilation matter and does its
avoidance represent an important design goal in future devices?
2. There were two type Ia, one type Ib, and one type III endoleak
in the 75% who were followed with computed tomography
scan. As you have pointed out, the strata polytetraﬂuoroethy-
lene material is located exterior to the metal scaffolding which
allows the material to billow out. An imaging cohort showed
extension of the anatomic neck related to this billowing. Inter-
estingly, there were very few type II endoleaks which have been
attributed to the ability of the fabric to cover the entire length of
the infrarenal aorta. Are you aware of any data using either pres-
sure wires or CardioMems pressure sensors regarding whether
the design of the AFX device allows the excessive or ongoing
transmission of pressure to the aneurysm wall? And, is there
any consequence?
3. I notice that you have used an ipsilateral cut down despite the
fact that the device has a percutaneous endovascular anerusym
repair (PEVAR) indication. Do you expect to adopt this prac-
tice in future, and if not, why not?
4. Finally, where do you ﬁt this device into your current armamen-
tarium? In what patients do you preferentially use this device?
Thank you for presenting your data.
Dr M. Burress Welborn III. Thank you very much for the
questions.The ﬁrst question regards neck dilatation. We oversize the
aortic neck for the AFX graft more than other products. In patients
with challenging necks we are more aggressive with oversizing.
Often we end up oversizing >20%. The proximal stent has very lit-
tle radial force. There is no indication from the original Powerlink
device (Endologix) investigational device exemption studies that
there was any neck dilatation. The AFX device is the second-gen-
eration of the Powerlink device so I expect no difference. I do not
think that AFX stent component has much effect on neck dilata-
tion. Clearly we will have to see what happens. The next issue is
whether or not that constant pressure from unattached graft will
result in neck dilation. We certainly have not seen this but this
needs to be considered. I think it is still too early to make any con-
clusions because our data represent only midterm results. Only
longer-term data will tell us if either mechanism results in aortic
neck dilation.
The second question concerns intrasac pressure. There are
some unpublished data from Cardiomems on intrasac pressure
with the Powerlink device. The intrasac pressure when you initially
put the graft in is quite high, but then after 45 to 60 days the intra-
sac pressure decreases to pressures that have been published for
other devices. There are no data that I am aware of that suggests
elevated intrasac pressures after placement of the AFX device.
The third question concerned PEVAR. I have been hesitant to
get into PEVAR. My partner does PEVAR. I do not perform
PEVAR because of personal reasons. I perform surgery on Friday
and the last thing I want to do is get a call about an access site
complication when I am spending time with my loved ones.
The ﬁnal question is, in which patients to I chose to place an
AFX device. The question is when do I use this device? My ques-
tion is when don’t I use the device? The AFX device is great for
saccular aneurysms. I think it is the ideal graft for saccular aneu-
rysms. The AFX device is great for normal aortic bifurcations
and the device is ideal for patients who have infrainguinal disease
that you are going to have to go back and intervene later. I think
the one pitfall is patients who have very large iliac artery aneurysms
in whom you do not have an aortic bifurcation on which you can
reliably seat the graft. The real strength of the graft is that its ﬁx-
ation is at the aortic bifurcation. The issues of the neck sealing
zone and neck coverage are important but the device uses the
aortic bifurcation as the primary site of ﬁxation. Patients with large
iliac aneurysm and compromised aortic bifurcations are, in my
opinion, not ideal candidates for the AFX device.
